100 Dots Connected: Reflecting on Eight Years of Conversations
The first edition of "Connecting the Dots" was published on September 29, 2017.…
The “Forcing Function” of JPM
Biopharma companies need to balance many critical priorities, especially those…
A Practical Guide to Biopharma Year-End Planning
As summer winds down and vacations (sadly) come to an end, it’s a natural time…
Medical Affairs Is Stepping Into the Future
The energy was palpable at the 2025 Medical Affairs Professional Society (MAPS)…
Your Biopharma Data Needs a Strategy
In the not-so-distant past, physician prescribing data was essentially a commodity with limited breadth or depth for the purposes of drug development…
Juggling Geographic Commercialization Priorities
Commercializing a pharmaceutical asset in one country is hard enough. Doing it on a global scale, with multiple country differences, is exponentially…
Medical Affairs: An Orchestra, Not a Horse Race
Every horse race has a starting bell, a push to move as fast as possible, and a finish line. In many ways, the launch of a new drug can feel similar.…
Three Big Mistakes
Over the past 20 years, The NemetzGroup has been involved in the launch of more than 50 different drugs and has had input into the strategic…
The Truth about Teams
When it comes to team performance and adherence to “best practices,” what works on paper or in a teambuilding workshop and what actually occurs are…
Patient Advocacy – Delivering on Patient Centricity in Drug Development
Historically, biopharma companies developed drugs for patients with an illness — but the illness was the primary focus. In recent years, much has…
Survival in Uncertain Times
Like so many seasoned industry professionals, we eagerly seek thought leader perspectives — on the current biopharma industry landscape; the…
Optimize Your Congress Planning
Regardless of your company or drug development stage, congress events are critical undertakings; they represent both a substantial opportunity and a…